Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection

APMIS

Volumn 117, Issue 9, 2009, Pages 660-671

  Hallander, Hans O ^a   Ljungman, Margaretha ^a   Jahnmatz, Maja ^a   Storsaeter, Jann ^b   Nilsson, Lennart ^c   Gustafsson, Lennart ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Booster; ELISA IgG anti Fim2 3; Fimbriae; Infection; Kinetics; Pertussis; Seroepidemiology; Sweden; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZA TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HEMAGGLUTININ; IMMUNOGLOBULIN G ANTIBODY; PENTAVAC; PERTACTIN; PLACEBO; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; BORDETELLA PERTUSSIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FIMBRIA; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOLOGICAL MEMORY; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PERTUSSIS; PHASE 1 CLINICAL TRIAL; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; REVACCINATION; SEROEPIDEMIOLOGY; SEROLOGY; SWEDEN; TETANUS; VACCINATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIMBRIAE PROTEINS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFANT; LONGITUDINAL STUDIES; PERTUSSIS VACCINE; SEROEPIDEMIOLOGIC STUDIES; SWEDEN; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 69449095972     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02521.x     Document Type: Article

References (31)

1. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005 18 : 326 382.
2. Medical Research Council. Relation between protection in children and results of laboratory tests. Br Med J 1956 2 : 454 462.
3. Mink CM, O'Brien CH, Wassilak S, Deforest A, Meade BD. Isotype and antigen specificity of pertussis agglutinins following whole-cell pertussis vaccination and infection with Bordetella pertussis. Infect Immun 1994 62 : 1118 1120.
4. Sako W. Studies on pertussis immunization. J Pediatr 1947 30 : 29 40.
5. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998 16 : 1901 1906.
6. Cherry JD, Heininger U. Antibody response patterns to Bordetella perussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. American Society for Microbiology 108th General Meeting, Boston, MA 2008.
7. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998 16 : 1907 1916.
8. Meade BD, Deforest A, Edwards KM, Romani TA, Lynn F, O'Brien CH, et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 1995 96 : 570 575.
9. WHO. WHO Expert Committee on Biological Standardization, 30th Report. World Health Organ Tech Rep Ser 1979 638 : 61 5.
10. Preston NW. Essential immunogens in human pertussis: the role of fimbriae. Dev Biol Stand 1985 61 : 137 141.
11. Robinson A, Ashworth LA, Irons LI. Serotyping Bordetella pertussis strains. Vaccine 1989 7 : 491 494.
12. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996 334 : 349 355.
13. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997 350 : 1569 1577.
14. Carlsson RM GL. Ten Year Report. Pertussis Surveillance in Sweden. Progress Report October 1, 1997-December 31, 2007. Smittskyddsinstitutet, 2008.
15. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006 118 : 978 984.
16. Olin P, Carlsson R-M, Johansen K, Hallander HO, Ljungman M, Svensson Å, et al. Vaccinationsuppföljning, Seroepidemiologisk tvärsnittsstudie 1997, Slutrapport. SMI:s rapportserie, 2004.
17. Hallander HO. Microbiological and serological diagnosis of pertussis. Clin Infect Dis 1999 28 (Suppl. 2 S99 106.
18. Reizenstein E, Hallander HO, Blackwelder WC, Kuhn I, Ljungman M, Mollby R. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods 1995 183 : 279 290.
19. Giammanco A, Chiarini A, Maple PA, Andrews N, Pebody R, Gay N, et al. European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine 2003 22 : 112 120.
20. Hallander HO, Cherry JD, Gustafsson L, Storsaeter J, Heininger U. Serological correlates of immunity to Bordetella pertussis cough illness. 108th ASM Meeting. Boston, MA 2008.
21. Tiru M, Hallander HO, Gustafsson L, Storsaeter J, Olin P. Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine 2000 18 : 2295 2306.
22. Hallander HO, Gustafsson L, Ljungman M, Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa: response to a first booster dose 3/-6/ years after the third vaccine dose. Vaccine 2005 23 : 5359 5364.
23. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 2003 21 : 3542 3549.
24. Barreto L, Guasparini R, Meekison W, Noya F, Young L, Mills E. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 2007 25 : 8172 8179.
25. Bailleux F, Coudeville L, Kolenc-Saban A, Bevilacqua J, Barreto L, Andre P. Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine 2008 26 : 3903 3908.
26. Heininger U, Cherry JD, Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 2004 38 : 591 594.
27. Thomas MG, Ashworth LA, Miller E, Lambert HP. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine. J Infect Dis 1989 160 : 838 845.
28. Cherry JD, Xing DX, Newland P, Patel K, Heininger U, Corbel MJ. Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. Clin Infect Dis 2004 38 : 502 507.
29. Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson R-M. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol 2005 43 : 2856 2865.
30. Poolman JT, Hallander HO. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev Vaccines 2007 6 : 47 56.
31. He Q, Makinen J, Berbers G, Mooi FR, Viljanen MK, Arvilommi H, et al. Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? J Infect Dis 2003 187 : 1200 1205.